The Directory of Pharma Companies and News


Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit

Biogen News

2016-06-01Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Progra...
2016-05-31Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Resp...
2016-05-30FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union
2016-05-27Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
2016-05-19Biogen Announces Webcast of Virtual Annual Meeting of Stockholders
2016-05-16Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs
2016-05-13Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B
2016-05-03Biogen Announces Intent to Spin off Its Hemophilia Business
2016-04-29Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
2016-04-27Biogen Appoints Michael Ehlers Executive Vice President, Research and Development
2016-04-21Biogen Reports First Quarter 2016 Revenues of $2.7 Billion
2016-04-20Data Presented at AAN Highlight Impact of ZINBRYTA™ (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its ...
2016-04-18TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
2016-04-14Biogen Joins in Celebration of World Hemophilia Day
2016-04-12Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Pat...
2016-04-01FLIXABI®, an Infliximab Biosimilar Candidate Referencing Remicade®, Receives Positive CHMP Opinion
2016-03-30Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer
2016-03-28Biogen to Present at the Goldman Sachs Alzheimer’s Symposium
2016-03-21Biogen to Report First Quarter 2016 Financial Results on April 21, 2016
2016-02-29Biogen to Present at the Cowen and Company 36th Annual Health Care Conference
2016-02-26Sobi and Biogen Receive Positive Opinion from CHMP for Alprolix® (rFIXFc) for the Treatment of Hemophilia B
2016-02-08Biogen Joins Pioneering Target Validation Collaboration
2016-02-04Biogen to Present at the Leerink Partners 5th Annual Global Healthcare Conference
2016-01-27Biogen 2015 Revenues Increase 11% to $10.8 Billion
2016-01-16BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union
2015-12-21Biogen to Report Fourth Quarter and Year End 2015 Financial Results on January 27, 2016
2015-12-18Biogen to Present at the 34th Annual J.P. Morgan Healthcare Conference
2015-12-08New Data Show ELOCTATE® and ALPROLIX® May Help Control Target Joint Bleeds in People with Hemophilia A and B
2015-11-24Sobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
2015-11-20Biogen Announces Benepali™ (Etanercept) is the First Biosimilar of Enbrel® to Receive a Positive Opinion from CHMP
2015-11-11Steven Holtzman to Retire from Biogen
2015-10-21Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
2015-10-21Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
2015-10-12Hemophilia Therapy from Largest Multi-Year Donation Now Available to Patients in Developing World
2015-10-09Biogen Announces Departure of Tony Kingsley
2015-10-08Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon...
2015-10-07New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Mu...
2015-10-05Biogen Announces Webcast of Investor R&D Day
2015-10-01Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, Including New TECFIDERA® Data Demonstratin...
2015-09-25Biogen and Sobi Receive Positive Opinion from CHMP for ELOCTA™ (rFVIIIFc) for the Treatment of Hemophilia A
2015-09-22Biogen to Report Third Quarter 2015 Financial Results on October 21, 2015
2015-09-11Biogen Named the Global Biotechnology Industry Leader on Dow Jones Sustainability World Index for Second Consecutive Yea...
2015-09-11Biogen Prices $6.0 Billion of Senior Unsecured Notes
2015-09-10CORRECTING and REPLACING Biogen to Present at Bank of America Merrill Lynch Global Healthcare Conference London
2015-09-09Biogen Licenses Mitsubishi Tanabe Pharma’s Phase 2 Molecule for Autoimmune Diseases
2015-09-08Biogen Enrolls First Patient in Global Phase 3 Study of Investigational Treatment Aducanumab (BIIB037) for Early Alzheim...
2015-09-08Biogen to Present at the Morgan Stanley Global Healthcare Conference
2015-09-02USPTO Dismisses Inter Partes Review Petition of Biogen’s Patent 514 for TECFIDERA® (Dimethyl Fumarate)
2015-08-18Biogen, the ALS Association and Columbia University Medical Center Collaborate to Drive Understanding of Genetic Influen...
2015-08-17Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B
2015-08-10Extension Study Data Supporting Long-Term Safety and Efficacy of Eloctate® Published in Haemophilia
2015-07-27Biogen Enters Collaboration with the Parkinson’s Institute and Clinical Center
2015-07-24Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion
2015-07-22Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Al...
2015-07-10Douglas Williams to Leave Biogen for Biotechnology Start-Up
2015-07-06Biogen to Report Second Quarter 2015 Financial Results on July 24, 2015
2015-07-02Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology
2015-06-26Biogen and Sobi Announce European Medicines Agency Validates ALPROLIX® (rFIXFc) Marketing Authorization Application
2015-06-23Biogen Achieves Carbon Neutrality
2015-06-18New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use
2015-06-10Biogen and Samsung Bioepis Announce New Data for Three Anti-TNF Biosimilar Development Candidates at EULAR 2015 Congress
2015-05-28Biogen 2015 Annual Shareholder Meeting Webcast
2015-05-20Biogen to Present at Bernstein’s 31st Annual Strategic Decisions Conference
2015-05-13Biogen Names Matt Griffiths as Chief Information Officer
2015-05-13Biogen to Present at the 2015 UBS Global Healthcare Conference
2015-05-07Biogen to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
2015-05-07Biogen Announces $5 Billion Share Repurchase Program
2015-04-29FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS
2015-04-28Biogen to Present at the 40th Annual Deutsche Bank Health Care Conference
2015-04-24Biogen Reports First Quarter 2015 Revenues of $2.6 Billion
2015-04-21PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy ...
2015-04-21International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction
2015-04-20TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
2015-04-14Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair
2015-04-07Biogen Data at AAN Annual Meeting Underscore Commitment to Advancing Patient Care in Neurology
2015-04-01Biogen to Report First Quarter 2015 Financial Results on April 24, 2015
2015-03-27European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) fo...
2015-03-23Biogen Idec Becomes Biogen
2015-03-20Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aduca...
2015-02-27Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX® Pediatric Study
2015-02-23Biogen Idec to Present at the Cowen and Company 35th Annual Healthcare Conference
2015-01-29Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.
E_CORE_WARNING Error in file Unknown at line 0: PHP Startup: Invalid library (appears to be a Zend Extension, try loading using from php.ini)